Gritstone Oncology Competitors

Kymera Therapeutics (NASDAQ:KYMR) and Gritstone Oncology (NASDAQ:GRTS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Kymera Therapeutics and Gritstone Oncology's net margins, return on equity and return on assets.

Institutional and Insider Ownership

37.8% of Kymera Therapeutics shares are held by institutional investors. Comparatively, 59.0% of Gritstone Oncology shares are held by institutional investors. 38.0% of Gritstone Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Kymera Therapeutics and Gritstone Oncology, as provided by MarketBeat.

Kymera Therapeutics presently has a consensus price target of $50.3333, suggesting a potential upside of 9.75%. Gritstone Oncology has a consensus price target of $22.3333, suggesting a potential upside of 64.34%. Given Gritstone Oncology's higher probable upside, analysts clearly believe Gritstone Oncology is more favorable than Kymera Therapeutics.

Earnings & Valuation

This table compares Kymera Therapeutics and Gritstone Oncology's top-line revenue, earnings per share and valuation.

Kymera Therapeutics has higher earnings, but lower revenue than Gritstone Oncology.

Summary

Kymera Therapeutics beats Gritstone Oncology on 5 of the 9 factors compared between the two stocks.

Gritstone Oncology (NASDAQ:GRTS) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Gritstone Oncology and BioCryst Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

59.0% of Gritstone Oncology shares are owned by institutional investors. Comparatively, 72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. 38.0% of Gritstone Oncology shares are owned by insiders. Comparatively, 4.3% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Gritstone Oncology has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 3.03, suggesting that its share price is 203% more volatile than the S&P 500.

Valuation & Earnings

This table compares Gritstone Oncology and BioCryst Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gritstone Oncology has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Gritstone Oncology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Gritstone Oncology and BioCryst Pharmaceuticals, as provided by MarketBeat.

Gritstone Oncology presently has a consensus target price of $22.3333, suggesting a potential upside of 64.34%. BioCryst Pharmaceuticals has a consensus target price of $11.3750, suggesting a potential upside of 4.17%. Given Gritstone Oncology's higher probable upside, equities analysts clearly believe Gritstone Oncology is more favorable than BioCryst Pharmaceuticals.

Gritstone Oncology (NASDAQ:GRTS) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.

Institutional and Insider Ownership

59.0% of Gritstone Oncology shares are owned by institutional investors. Comparatively, 94.3% of bluebird bio shares are owned by institutional investors. 38.0% of Gritstone Oncology shares are owned by company insiders. Comparatively, 3.6% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Gritstone Oncology and bluebird bio, as reported by MarketBeat.

Gritstone Oncology presently has a consensus price target of $22.3333, indicating a potential upside of 64.34%. bluebird bio has a consensus price target of $68.4667, indicating a potential upside of 145.05%. Given bluebird bio's higher possible upside, analysts plainly believe bluebird bio is more favorable than Gritstone Oncology.

Profitability

This table compares Gritstone Oncology and bluebird bio's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Gritstone Oncology and bluebird bio's top-line revenue, earnings per share and valuation.

Gritstone Oncology has higher earnings, but lower revenue than bluebird bio. Gritstone Oncology is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Gritstone Oncology has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500.

Summary

bluebird bio beats Gritstone Oncology on 9 of the 14 factors compared between the two stocks.

Gritstone Oncology (NASDAQ:GRTS) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Gritstone Oncology and Vericel, as reported by MarketBeat.com.

Gritstone Oncology currently has a consensus target price of $22.3333, indicating a potential upside of 64.34%. Vericel has a consensus target price of $49.00, indicating a potential upside of 21.26%. Given Gritstone Oncology's higher probable upside, analysts clearly believe Gritstone Oncology is more favorable than Vericel.

Valuation and Earnings

This table compares Gritstone Oncology and Vericel's gross revenue, earnings per share (EPS) and valuation.

Vericel has higher revenue and earnings than Gritstone Oncology. Gritstone Oncology is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Gritstone Oncology has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Vericel has a beta of 3.11, indicating that its stock price is 211% more volatile than the S&P 500.

Insider & Institutional Ownership

59.0% of Gritstone Oncology shares are owned by institutional investors. Comparatively, 93.1% of Vericel shares are owned by institutional investors. 38.0% of Gritstone Oncology shares are owned by company insiders. Comparatively, 4.3% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Gritstone Oncology and Vericel's net margins, return on equity and return on assets.

Summary

Vericel beats Gritstone Oncology on 10 of the 14 factors compared between the two stocks.

Gritstone Oncology (NASDAQ:GRTS) and Scholar Rock (NASDAQ:SRRK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Profitability

This table compares Gritstone Oncology and Scholar Rock's net margins, return on equity and return on assets.

Volatility and Risk

Gritstone Oncology has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Gritstone Oncology and Scholar Rock, as provided by MarketBeat.com.

Gritstone Oncology presently has a consensus target price of $22.3333, indicating a potential upside of 64.34%. Scholar Rock has a consensus target price of $61.60, indicating a potential upside of 21.74%. Given Gritstone Oncology's higher probable upside, equities analysts plainly believe Gritstone Oncology is more favorable than Scholar Rock.

Institutional and Insider Ownership

59.0% of Gritstone Oncology shares are held by institutional investors. Comparatively, 61.9% of Scholar Rock shares are held by institutional investors. 38.0% of Gritstone Oncology shares are held by insiders. Comparatively, 24.6% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Gritstone Oncology and Scholar Rock's gross revenue, earnings per share and valuation.

Scholar Rock has higher revenue and earnings than Gritstone Oncology. Scholar Rock is trading at a lower price-to-earnings ratio than Gritstone Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Scholar Rock beats Gritstone Oncology on 9 of the 14 factors compared between the two stocks.

Gritstone Oncology (NASDAQ:GRTS) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Insider and Institutional Ownership

59.0% of Gritstone Oncology shares are owned by institutional investors. Comparatively, 8.5% of Ocugen shares are owned by institutional investors. 38.0% of Gritstone Oncology shares are owned by insiders. Comparatively, 3.5% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for Gritstone Oncology and Ocugen, as reported by MarketBeat.

Gritstone Oncology presently has a consensus target price of $22.3333, suggesting a potential upside of 64.34%. Ocugen has a consensus target price of $4.80, suggesting a potential downside of 46.49%. Given Gritstone Oncology's higher possible upside, equities analysts clearly believe Gritstone Oncology is more favorable than Ocugen.

Profitability

This table compares Gritstone Oncology and Ocugen's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Gritstone Oncology and Ocugen's top-line revenue, earnings per share and valuation.

Ocugen has lower revenue, but higher earnings than Gritstone Oncology. Ocugen is trading at a lower price-to-earnings ratio than Gritstone Oncology, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Gritstone Oncology has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.56, indicating that its stock price is 256% more volatile than the S&P 500.

Summary

Ocugen beats Gritstone Oncology on 8 of the 13 factors compared between the two stocks.